


Unique Lipid Signatures of Extracellular Vesicles from the Airways of Asthmatics

Hough, K.P., BS¹, L. Wilson, BS^{4,5}, J.L. Trevor, MD¹, J.G. Strenkowski, BS¹, N. Maina, MD, PhD¹, Y. Kim, PhD¹, M.L. Spell, BS², Y. Wang, PhD¹, D. Chanda, PhD¹, J. Rodriguez Dager BS¹, N. Sharma, MD¹, C. Miranda, MD, PhD¹, V.B. Antony, MD¹, M.T. Dransfield, MD¹, D.D. Chaplin, MD, PhD³, C. Steele, PhD¹, S. Barnes, PhD^{4,5}, S.R. Duncan, MD¹, J.K. Prasain, PhD^{4,}
⁵, V.J. Thannickal, MD¹, and J.S. Deshane, PhD^{1*}


¹Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, ²Center for Aids Research, ³Department of Microbiology, ⁴Department of Pharmacology and Toxicology, and ⁵Targeted Metabolomics and Proteomics Laboratory, University of Alabama at Birmingham, Birmingham, AL

Supplementary Figure 1




Supplementary Figure 1 – Representative histograms of airway exosomes stained with antibodies for surface markers: CD63, HLA-DR, CD54, and CD36. (a) CD63, a tetraspanin used as an exosome marker. (b) HLA-DR, a class II antigen presentation molecule. (c) CD54, also known as ICAM-1, a surface integrin molecule. (d) CD36, a pattern-recognition scavenger protein (Healthy subjects n=9; Asthmatic subjects n=9).

Supplementary Figure 2




Supplementary Figure 2 – ImageStream analysis of airway exosomes from healthy and asthmatic subjects.
(a) Representative fluorescence images from ImageStream of airway exosomes from four healthy and asthmatic subjects. Exosomes were stained with antibodies for surface markers: CD63, HLA-DR, and CD54 (Healthy subjects n=6; Asthmatic subjects n=6).

Supplementary Figure 3




Supplementary Figure 3 – Airway exosomes have higher lipid content than protein, as assessed by PKH26, a lipophilic dye, and CFSE for protein using ImageStream. Differences in protein and lipid content was not seen between study groups (Mann Whitney T test, $*<0.05$; Healthy subjects $n = 4$; Asthmatic subjects $n = 4$).

Supplementary Figure 4




Supplementary Figure 4 – Volcano plot of the bivariate analysis (performed on Metaboanalyst 3.0) of identified lipids from BAL exosomes. Y-axis displays significance, represented as $-\log(p\text{-value})$, and the x-axis displays log base-2 fold-change. The horizontal dotted line marks the 0.05 p-value cutoff. Significant data points were enlarged and colored purple for illustration purposes. (a) Healthy subjects versus asthmatics, non-SHS exposed. LIPID244 (phosphatidylglycerol 34:2, $p=0.023$) was found to be more abundant in healthy subjects. (b) Healthy subjects versus SHS exposed healthy subjects. Identified lipids were all higher in healthy subjects. LIPID 58 (monosialoganglioside 28:3, 264.2 m/z, $p=0.024$), LIPID59 (monosialoganglioside 28:3, 282.2 m/z, $p=0.024$), LIPID61 (ceramide-phosphate 28:1, 264.2 m/z, $p=0.024$), LIPID63 (ceramide-phosphate 28:1, 282.2 m/z, $p=0.024$), LIPID82 (mannosyl-diinositol phosphoryl-ceramide 26:2, 264.2 m/z, $p=0.024$), LIPID83 (mannosyl-diinositol phosphoryl-ceramide 26:2, 282.2 m/z, $p=0.024$), LIPID86 (ceramide 34:2, $p=0.023$), LIPID88 (ceramide-phosphate 28:0, $p=0.024$), and LIPID244 (phosphatidylglycerol 34:2, $p=0.040$). (c) Asthmatics versus SHS exposed asthmatics. LIPID86 (ceramide 34:2, $p=0.012$) was significantly higher in asthmatics. (d) Healthy subjects exposed to SHS versus asthmatics exposed to SHS. LIPID162 (sphingomyelin 34:1, $p=0.046$) was significantly higher in asthmatics exposed to SHS (Healthy subjects n = 9 (no SHS n=4, +SHS n = 5); Asthmatic subjects n =11 (no SHS n=6, +SHS n = 5)).

Supplementary Figure 5




Supplementary Figure 5 – Mass spectrum of ceramide-phosphate 28:1 from BAL exosomes. Ceramide-phosphate 28:1 was detected from the SWATH lipidomics reported in Table 2. The presence of this modified lipid species was confirmed by targeted lipidomics. The red arrow pointing to the mass/charge ratio of 78.9565 m/z corresponds to the phosphate of ceramide-phosphate 28:1.

Supplementary Figure 6



Supplementary Figure 6 – Mass spectrum of trihexosylceramide 40:1. Trihexosylceramide 40:1 was detected from the SWATH lipidomics reported in Supplementary Table 2. The presence of this lipid species was confirmed by targeted lipidomics. The proposed structure for trihexosylceramide 40:1 is also represented in the mass spectrum on the left-side. The red arrows indicate the mass difference for the hexose.

Supplementary Figure 7



Supplementary Figure 7 – Variable Importance in Projection (VIP) scores from the partial least squares (PLS) analysis (performed on Metaboanalyst 3.0) of identified lipids from BAL exosomes. Higher VIP scores indicate important players in the PLS model. (a) Healthy subjects versus asthmatics, non-SHS exposed. The significant lipid, LIPID244, is phosphatidylglycerol 34:2. (b). Healthy subjects versus SHS exposed healthy subjects. The important lipids, LIPID61, LIPID62 and LIPID88, are ceramide-phosphate 28:1 (264.2 m/z), ceramide-phosphate 28:1 (282.2 m/z), and ceramide-phosphate 28:0, respectively. (c) Asthmatics versus SHS exposed asthmatics. The significant lipid, LIPID86, is ceramide 34:2, and LIPID88 ceramide-phosphate 28:0. (d) Healthy subjects exposed to SHS versus asthmatics exposed to SHS. The significant lipids, LIPID 429 and LIPID 175, are sphingomyelin 42:3 and sphingomyelin 32:1, respectively (Healthy subjects n = 9 (no SHS n=4, +SHS n = 5); Asthmatic subjects n =11 (no SHS n=6, +SHS n = 5)).

Supplementary Table 2 – List of 91 lipids and their bivariate analysis after filtering out study groups with missing values.

Annotation	Expanded Annotation	A (N=6)			AS (N=5)			H (N=4)			HS (N=5)			Wilcoxon Rank Test			T-test	
		LIPIDID	Mean	Median	Mean	Median	Mean	Median	AS vs HS	A vs AS	H vs A	H vs HS	A vs H	AS vs HS	A vs AS	H vs HS		
SM 34:1:2 (SM)	Sphingomyelin 34:1:2	LIPID162	0.328067	0.62024	0.08551	-0.1695	0.009385	-0.2237	0.046	-0.62302	0.046	0.415	0.204	0.093	0.38	0.359	0.132	
SM 34:0:2 (SM)	Sphingomyelin 34:0:2	LIPID169	0.199624	-0.52572	0.16211	-0.57729	0.010643	-0.49582	-0.41378	-0.5405	0.42	0.465	0.237	0.151	0.139	0.483	0.411	
PC 30:0 (PC 104)	Phosphatidylcholine 30:0	LIPID172	-0.4815	-0.130729	-0.412291	-0.4177	-0.03944	-0.33733	-0.38161	-0.35339	0.341	0.429	0.458	0.452	0.196	0.468	0.411	
PC 30:0 (LPC)	Lyso-Phosphatidylcholine 30:0	LIPID173	0.239603	-0.47404	0.172282	-0.53558	-0.08026	-0.46012	-0.3956	-0.56524	0.213	0.465	0.459	0.455	0.166	0.467	0.346	
PC 30:0 (PC)	Phosphatidylcholine 30:0	LIPID174	0.202542	-0.52591	0.165802	-0.58857	-0.02696	-0.49692	-0.38728	-0.59127	0.213	0.465	0.303	0.208	0.171	0.481	0.389	
SM 32:1:4 (SM)	Sphingomyelin 32:1:4	LIPID175	0.006023	-0.48047	0.733365	-0.23065	-0.44951	-0.45583	-0.38099	-0.48047	0.086	0.5	0.448	0.069	0.186	0.212	0.186	
SM 34:1:3 (SM)	Sphingomyelin 34:1:3	LIPID187	-0.006339	-0.57357	0.394135	-0.54292	0.051572	-0.41876	-0.42773	-0.55456	0.343	0.213	0.301	0.075	0.123	0.303	0.467	
PC O-32:0 (LPC)	Ether-linked Lyso-Phosphatidylcholine 32:0	LIPID189	-0.01842	-0.55392	0.491132	-0.54714	-0.02947	-0.42859	-0.44564	-0.48321	0.5	0.213	0.301	0.453	0.106	0.261	0.493	
PC O-32:0 (PC)	Ether-linked Phosphatidylcholine 32:0	LIPID190	-0.04991	-0.56569	0.503803	-0.5428	-0.06804	-0.46602	-0.38948	-0.55483	0.213	0.301	0.151	0.118	0.242	0.489	0.237	
PC 32:2 (LPC)	Lyso-Phosphatidylcholine 32:2	LIPID199	0.048395	-0.48451	-0.07785	-0.44018	0.541021	-0.27597	-0.41328	-0.56082	0.198	0.5	0.178	0.104	0.175	0.412	0.294	
PC 32:2 (PC)	Phosphatidylcholine 32:2	LIPID200	0.104235	-0.49012	-0.08804	-0.42789	0.479676	-0.31669	-0.42078	-0.54783	0.198	0.39	0.133	0.072	0.147	0.377	0.343	
SM 36:1:2 (SM)	Sphingomyelin 36:1:2	LIPID202	0.058751	-0.5535	0.253687	-0.61625	0.070411	-0.44239	-0.38052	-0.58693	0.273	0.395	0.378	0.151	0.17	0.396	0.494	
PC 32:1 (PC 104)	Phosphatidylcholine 32:1	LIPID205	0.179646	-0.39343	0.004398	-0.32303	0.309763	-0.32228	-0.46778	-0.71241	0.062	0.329	0.339	0.072	0.107	0.453	0.135	
PC 32:1 (LPC)	Lyso-Phosphatidylcholine 32:1	LIPID206	0.182795	-0.52196	0.007559	-0.53894	0.241813	-0.38985	-0.42036	-0.56927	0.213	0.465	0.237	0.075	0.166	0.403	0.474	
PC 32:1 (PC)	Phosphatidylcholine 32:1	LIPID207	0.50335	-0.48176	0.03212	-0.56706	0.196362	-0.162	0.5	0.303	0.075	0.185	0.424	0.48	0.211	0.469	0.211	
SM 36:0:2 (SM)	Sphingomyelin 36:0:2	LIPID209	0.136552	-0.44011	0.167335	-0.6498	0.077198	-0.38203	-0.39316	-0.59264	0.42	0.5	0.459	0.107	0.191	0.484	0.469	
PC 32:0 (PC 104)	Phosphatidylcholine 32:0	LIPID210	0.203123	-0.50813	0.071084	-0.55421	0.07285	-0.42544	-0.37311	-0.5225	0.5	0.465	0.303	0.075	0.186	0.433	0.204	
PC 32:0 (LPC)	Lyso-Phosphatidylcholine 32:0	LIPID211	0.144765	-0.49553	0.23496	-0.59838	0.016965	-0.46349	-0.42225	-0.60805	0.273	0.465	0.378	0.151	0.138	0.453	0.436	
PC 32:0 (PC)	Phosphatidylcholine 32:0	LIPID213	0.112204	-0.44366	0.239053	-0.65291	0.039017	-0.42797	-0.40491	-0.63838	0.273	0.465	0.378	0.107	0.16	0.434	0.462	
SM 34:1:4 (SM)	Sphingomyelin 34:1:4	LIPID214	-0.119147	-0.54443	0.444805	-0.53336	-0.22325	-0.52433	-0.40918	-0.55627	0.338	0.463	0.5	0.451	0.109	0.345	0.313	
SM 36:2:3 (SM)	Sphingomyelin 36:2:3	LIPID230	0.100972	-0.52238	0.327811	-0.49884	-0.09289	-0.48885	-0.37466	-0.49331	0.341	0.358	0.5	0.451	0.135	0.389	0.401	
PC O-34:1 (LPC)	Ether-linked Lyso-Phosphatidylcholine 34:1	LIPID238	0.073018	-0.61687	0.230173	-0.53813	0.029717	-0.38886	-0.34157	-0.59145	0.162	0.267	0.301	0.279	0.173	0.418	0.478	
PC O-34:1 (PC)	Ether-linked Phosphatidylcholine 34:1	LIPID239	0.08819	-0.63942	0.19898	-0.57737	-0.00336	-0.46619	-0.30212	-0.58708	0.213	0.327	0.178	0.151	0.222	0.442	0.304	
SM 36:1:3 (SM)	Sphingomyelin 36:1:3	LIPID242	-0.06249	-0.58553	0.573768	-0.47104	-0.11435	-0.48148	-0.4073	-0.58594	0.162	0.129	0.301	0.151	0.105	0.21	0.465	
PG 34:2 (-PG)	Phosphatidylglycerol 34:2	LIPID244	-0.5864	-0.87154	-0.06524	0.174447	-0.4074	-0.4074	-0.87154	0.232	0.104	0.023	0.04	0.202	0.076	0.001	0.006	
PC O-34:0 (LPC)	Ether-linked Lyso-Phosphatidylcholine 34:0	LIPID246	-0.24695	-0.5133	0.69478	-0.4699	-0.02253	-0.32544	-0.4731	0.5	0.167	0.335	0.5	0.1	0.116	0.311	0.191	
PC O-34:0 (PC)	Ether-linked Phosphatidylcholine 34:0	LIPID247	-0.13449	-0.5329	0.65501	-0.41714	-0.042038	-0.4782	-0.48221	0.273	0.129	0.415	0.406	0.09	0.158	0.457	0.191	
SM 38:3:2 (SM)	Sphingomyelin 38:3:2	LIPID262	0.300381	-0.45796	-0.11881	-0.44217	-0.138948	-0.36181	-0.35346	-0.4346	0.341	0.335	0.204	0.175	0.236	0.433	0.177	
PC 34:3 (LPC)	Sphingomyelin 38:3:2	LIPID265	0.217167	-0.51735	-0.46298	-0.17101	-0.46471	-0.197706	-0.38203	-0.37606	0.4809	0.273	0.215	0.237	0.107	0.157	0.365	0.492
PC 34:3 (PC)	Phosphatidylcholine 34:3	LIPID267	0.191151	-0.46298	-0.17101	-0.45815	0.406196	-0.36141	-0.38332	-0.48526	0.162	0.464	0.181	0.075	0.178	0.29	0.411	
SM 38:2:2 (SM)	Sphingomyelin 38:2:2	LIPID274	0.249917	-0.49098	-0.01088	-0.53867	-0.149014	-0.44091	-0.40031	-0.55274	0.213	0.465	0.303	0.075	0.168	0.359	0.456	
PC 34:2 (PC 104)	Phosphatidylcholine 34:2	LIPID280	0.232438	-0.48464	0.02925	-0.45786	-0.070721	-0.41976	-0.45786	-0.45786	0.377	0.266	0.459	0.453	0.272	0.401	0.368	
PC 34:2 (LPC)	Lyso-Phosphatidylcholine 34:2	LIPID281	0.30286	-0.45456	-0.00251	-0.47557	0.051883	-0.42306	-0.402									

Annotation	Wilcoxon Rank Test						T-test						
	A (N=6)			H (N=4)			AS (N=5)			HS (N=5)			
	Expanded Annotation		LIPIDID	Mean	Median	Mean	Median	Mean	Median	AS vs HS	A vs AS	H vs HS	A vs H
Sphingomyelin 42:2:2	LIPID437	0.203391	-0.57914	0.162372	-0.10188	0.034839	0.175017	-0.43431	-0.68949	0.21	0.358	0.301	0.107
SM 42:2:2 (SM)	LIPID439	-0.3985	-0.7071	0.166691	-0.7071	0.397913	0.365494	-0.0682	-0.7071	0.454	0.379	0.121	0.415
PC 38:2 (PC 104)	LIPID440	0.015894	-0.50824	0.474515	0.112931	-0.27108	-0.119	-0.27672	-0.57556	0.307	0.294	0.415	0.199
PC 38:2 (LPC)	LIPID442	0.132086	-0.60483	0.278695	-0.28357	-0.090668	0.056177	-0.43666	-0.64882	0.121	0.241	0.213	0.157
PC 38:2 (PC)	LIPID445	0.188176	-0.52915	0.293452	-0.24363	-0.06514	0.150488	-0.46715	-0.66107	0.273	0.213	0.415	0.249
SM 42:1:2 (SM)	LIPID445	0.188176	-0.52915	0.293452	-0.24363	-0.06514	0.150488	-0.46715	-0.66107	0.273	0.213	0.415	0.249
Cer 30:0:4 (LCB 18:1:2:2H20,LCB 18:0:3:3H20)	LIPID54	0.238289	-0.63914	-0.383533	-0.63914	0.764119	0.877535	-0.51191	-0.63914	0.366	0.292	0.082	0.256
GM3 28:3:2 (LCB 18:1:2:2H20,LCB 18:0:3:3H20)	LIPID58	0.475274	0.533479	-0.5914	-0.54658	0.908965	0.889236	-0.7061	-0.68139	0.271	0.126	0.303	0.024
GM3 28:3:2 (LCB 18:1:2:2H20,LCB 18:0:3:2H20)	LIPID59	0.424552	0.400448	-0.61264	-0.58951	0.939582	0.902401	-0.64848	-0.64529	0.5	0.126	0.303	0.024
CerP 28:1:2 (LCB 18:1:2:2H20,LCB 18:0:3:3H20)	LIPID61	0.584071	0.628632	-0.66189	-0.66255	0.93041	0.940448	-0.78332	-0.75562	0.341	0.055	0.237	0.024
CerP 28:1:2 (LCB 18:1:2:2H20,LCB 18:0:3:2H20)	LIPID63	0.552456	0.612457	-0.64766	-0.6604	0.890288	0.968685	-0.72752	-0.6788	0.459	0.119	0.055	0.237
GM3 28:1:2 (LCB 18:1:2:2H20,LCB 18:0:3:3H20)	LIPID65	-0.156998	-0.48371	-0.12913	-0.05675	0.021285	-0.15505	0.304076	-0.29215	0.417	0.321	0.263	0.275
GM3 28:1:2 (LCB 18:0:2:2H20)	LIPID66	0.393734	0.728264	-0.55939	-0.67503	0.785642	1.073412	-0.54233	-0.33387	0.458	0.126	0.337	0.103
Monosialoganglioside 28:1:2	LIPID67	0.116019	-0.56524	-0.37758	-0.31347	0.200584	0.268279	0.07789	-0.15603	0.341	0.237	0.024	0.291
Monosialoganglioside 28:1:2	LIPID69	-0.25261	-0.78557	0.546063	0.494921	-0.29172	-0.03667	-0.78557	0.333	0.196	0.5	0.448	0.370
Ceramide-phosphate 28:0:2	LIPID70	0.341872	0.341053	0.31474	-0.07634	-0.6379	-0.79622	0.147	0.126	0.5	0.082	0.098	0.109
M(IP)2C 26:1:2 (LCB 18:1:2:2H20,LCB 18:0:3:2H20)	LIPID71	-0.08225	-0.24741	0.175888	0.428131	0.294336	-0.44181	-0.31236	-0.81162	0.26	0.325	0.5	0.311
M(IP)2C 26:1:2 (LCB 18:1:2:2H20,LCB 18:0:3:2H20)	LIPID82	0.528225	0.49386	-0.68891	-0.6959	0.926985	1.064152	-0.68558	-0.70388	0.5	0.074	0.378	0.024
M(IP)2C 26:1:2 (LCB 18:1:2:2H20,LCB 18:0:3:3H20)	LIPID83	0.511703	0.407853	-0.6668	-0.67183	0.878144	0.975846	-0.64856	-0.67349	0.5	0.074	0.237	0.024
Cer 34:2:3 (LCB 18:2:2:2H20,LCB 18:1:3:3H20)	LIPID86	0.840357	0.415264	-0.7136	-0.60745	0.681048	0.720745	-0.83967	-1.18353	0.417	0.012	0.378	0.003
CerP 28:0:3 (LCB 18:0:2:2H20)	LIPID87	0.246097	0.710426	-0.58195	-1.10004	0.819234	0.728175	-0.36876	-1.10004	0.454	0.156	0.23	0.095
CerP 28:0:3 (LCB 18:1:2:2H20,LCB 18:0:3:2H20)	LIPID88	0.567665	0.612801	-0.7117	-0.7084	0.974409	1.00462	-0.74356	-0.73968	0.42	0.042	0.378	0.024
M(IP)2C 26:0:4 (LCB 18:1:2:2H20,LCB 18:0:3:3H20)	LIPID89	0.445933	0.160909	-0.51846	-0.8135	0.257923	0.239637	-0.223	-0.4961	0.419	0.126	0.5	0.151
M(IP)2C 26:0:4 (LCB 18:0:2:2H20,LCB 18:0:3:3H20)	LIPID90	0.469993	0.442493	-0.64777	-0.57109	0.848298	0.888239	-0.59486	-0.62972	0.419	0.126	0.459	0.024
M(IP)2C 26:0:4 (LCB 18:1:2:2H20,LCB 18:0:3:2H20)	LIPID91	0.392839	-0.38748	-0.25709	-0.62227	-0.17164	-0.2603	-0.077	-0.18418	0.341	0.463	0.456	0.35
Hex3Cer 40:1:2 (LCB 18:0:2:2H20)	LIPID96	0.512331	0.6683	-0.52396	-0.46642	0.7218	0.798744	-0.66828	-0.65747	0.271	0.126	0.458	0.127
Hex3Cer 40:1:2 (LCB 18:0:2:H2O)	LIPID98	0.505772	0.575519	-0.60055	-0.49097	0.631701	0.903898	-0.51173	-0.35148	0.268	0.126	0.458	0.126
										0.311	0.311	0.458	0.439
										0.126	0.126	0.458	0.032